FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA Peptide Reclassification 2026: What It Means for Providers The Blacklisting of Peptides What Peptides Are Legal in the U.S.? Understanding FDA Approval, Compounding, and the Legal Gray Areas FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List